Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13177778 | 0.83 | SMN1; SMN2 (0.43) | SMN1; SMN2HSD11B1HRH3KDM4EKMT2A | |
| SCHEMBL824152 | 0.80 | SMN1; SMN2 (0.45) | SMN1; SMN2HSD11B1HRH3KDM4EKMT2A | |
| SCHEMBL25147587 | 0.76 | SMN1; SMN2 (0.47) | SMN1; SMN2HSD11B1KDM4EKMT2A | |
| SCHEMBL16928372 | 0.76 | SMN1; SMN2 (0.47) | SMN1; SMN2HSD11B1HRH3KDM4EKMT2A | |
| SCHEMBL25147585 | 0.76 | SMN1; SMN2 (0.47) | SMN1; SMN2HSD11B1KDM4EKMT2A | |
| SCHEMBL15806904 | 0.76 | SMN1; SMN2 (0.42) | SMN1; SMN2HSD11B1HRH3KDM4EKMT2A | |
| SCHEMBL3476561 | 0.76 | SMN1; SMN2 (0.47) | SMN1; SMN2HSD11B1KDM4EKMT2A | |
| SCHEMBL8282582 | 0.76 | HSD17B10 (0.41) | SMN1; SMN2 | |
| SCHEMBL8283376 | 0.75 | NCF1 (0.37) | HRH3 | |
| SCHEMBL24288645 | 0.74 | SMN1; SMN2 (0.41) | SMN1; SMN2HSD11B1HRH3KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10695346-B2 | 4,6-pyrimidinylene derivatives and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20180110778-A1 | 4,6-PYRIMIDINYLENE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10695346-B2 | 4,6-pyrimidinylene derivatives and uses thereof | CDK3, CDK1, CDK14 | SMN1; SMN2 1640/4885HSD11B1 2324/4885HRH3 2385/4885 |
| US-20180110778-A1 | 4,6-PYRIMIDINYLENE DERIVATIVES AND USES THEREOF | CDKL4, CDKL5, PIP5K1A | SMN1; SMN2 2185/4885HSD11B1 2662/4885HRH3 2842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.